Clinical aspects of COX-2 inhibitors

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 267-274

  Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLOSULIDE; IBUPROFEN; MELOXICAM; NABUMETOME; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; NEPHROTOXICITY; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS;

EID: 0032807820     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552202     Document Type: Conference Paper

References (32)

1. Vane, J.R., Botting, R.M. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997, 26 (Suppl. 1): 2-10.
2. Jouzeau, J.Y., Terlain, B., Abid, A., Nedelac, E., Netter, P. Cyclooxygenase isoenzymes. Drugs 1997, 53: 563-82.
3. Needleman, P., Isakson, P.C. The discovery and function of COX-2. J Rheumatol 1997, 24 (Suppl. 49): 6-8.
4. O'Banion, M.K, Sadowski, H.B., Winn, V., Young, D.A. A serum and glucocorticoid regulated 4-kilobase mRNA encodes a cyclooxygenase related protein. J Biol Chem 1991, 266: 23261-7.
5. Crofford, L.J. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997, 24 (Suppl. 49), 15-19.
6. Emery, P. Differentiating nonsteroidal anti-inflammatory drugs: Risks vs benefits. Scand J Rheumatol 1996, (Suppl. 105): 1-46.
7. Langman, M.J.S., Weil, J., Wainwright, P. et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343: 1075-8.
8. Singh, G., Terry, R., Ramey, D.R. et al. Comparative GI toxicity of NSAIDs. Arthritis Rheum 1997, 40 (Suppl.): 507a.
9. Cook, M.E., Wallin, J.D., Thakur, V.D. et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997, 24: 1137-44.
10. Frolich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997, 18: 30-4.
11. Dvornik, D.M. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. J Rheumatol 1997, 24 (Suppl. 47): 40-7.
12. Vergne, P., Bertin, P., Ligre, B. et al. Differential inhibition of COX-1 and COX-2 by nonsteroidal anti-inflammatory drugs in cultured synovial cells. Arthritis Rheum 1997, 40 (Suppl.): 375a.
13. Lopez-Armada, M.J., Hernandez, P., Sanchez-Pernaute, O. et al. Comparison between a COX-2 selective inhibitor (meloxicam) and a nonselective NSAID (diclofenac) in acute antigen-induced arthritis. Arthritis Rheum 1997, 40 (Suppl.): 410a.
14. Meade, E.A., Smith, W.L. De Witt, D.L. Differential inhibition of prostaglandin enderoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993, 268: 6610-14.
15. Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J., Vane, J.R. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994, 90: 163-697.
16. Cohn, S.M., Schloemann, S., Tessner, T., Siebert, K., Stenson, W.F. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest 1997, 99: 1367-79.
17. Kaufmann, W.E., Andreasson, K.I., Isakson, P.C., Worley, P.F. Cyclooxygenases and the central nervous system. Prostaglandins 1997, 54: 601-24.
18. Rogers, J. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43: 1609-11.
19. Stewart, W.F., Kawas, C., Carrada, M., Metter, E.J. Risk of Alzheimer's disease and duration of NSAIDs use. Neurology 1997, 48: 626-32.
20. Wilkens, R.F. An overview of the long-term safety experience of nabumetone. Drugs 1990, 40 (Suppl. 5): 34-7.
21. Blower, P.R. The unique pharmacological profile of nabumetone. J Rheumatol 1992, 19 (Suppl. 36): 13-19.
22. Roth, S.H., Tindall, E.A., Jain, A.K. et al. A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprotol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993, 153: 2565-71.
23. Distel, M., Mueller, C., Bluhmkl, E., Fries, J. Safety of meloxicam: A global analysis of clinical trials. Br J Rheumatol 1996, 35 (Suppl. 1): 68-77.
24. Barner, A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996, 25 (Suppl. 102): 29-37.
25. Distel, M., Degner, F.L., Bluhmkl, E. Meloxicam results in fewer gastrointestinal adverse events than standard non-steroidal anti-inflammatory drugs: Findings from a meta-analysis. Rheuma-tol Eur 1996, 25: Abst 441.
26. Cipollini, F. et al. Endoscopic assessment of the effects of nimesulide on the gastric mucosa: Comparison with indomethacin. Curr Ther Res 1989, 45: 1042-8.
27. 4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1988, 1: 35-9.
28. Maziasz, T., Seibert, K., Khan, N., Paulson, S., Isakson, P. Preclinical pharmacology of celecoxib and demonstration of superior GI safety compared with NSAIDs in dogs. Arthritis Rheum 1997, 40 (Suppl.): 983a.
29. Hubbard, R.C., Koepp, R., Yu, S.S., Talwalker, S., Geis, G.S. Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. Arthritis Rheum 1997, 40 (Suppl.): 125a.
30. Lanza, F.L., Callison, D.A., Hubbard, R.C., Shawn, S.U., Talwalker, S., Geis, G.S. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a COX-2 selective inhibitor. Arthritis Rheum 1997, 40 (Suppl.): 373a.
31. Ehrich, E., Schnitzer, T., Kivitz, A. et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and in a 6-week placebo controlled study. Arthritis Rheum 1997, 40 (Suppl.): 330a.
32. Lansa, F., Simon, T., Quan, H. et al. Selective inhibition of COX-2 with MK-966 is associated with less gastric duodenal damage than aspirin or ibuprofen. Am Gastroentol Assoc Am Assoc Study Liver Dis (May 11-14) 1997.